Surpassing expectations via joint innovation

Juul Zwinkels News releases

Developing the next generation hydrogel using Pepscan’s RGD bicyclic peptides Pepscan and 13 other partners participated in the Horizon 2020 – Marie Skodowska-Curie project BIOGEL’s consortium. “Our primary task was to fabricate cell-specific bicyclic peptides that can be utilized to modify the hydrogels with specific integrin-binding domains, in this case RGD, to direct cells,” says Peter Timmerman, CSO at Pepscan. Paul Kouwer, Assistant Professor at Radboud University, adds: “Our preliminary results show a thousand-fold increase in cell binding. You can …

Pepscan at Immuno-Oncology Summit/TMB & Neoantigen Stream

Juul Zwinkels News releases

“A great opportunity to share our knowledge and experience!” The battle to outsmart cancer isn’t won yet. Scientists are continuously looking for new and better approaches to tackle this disease. Cancer treatment with a personalized neoantigen peptide vaccine is a rising star among these approaches. Recently Pepscan has positioned itself as a critical partner in several collaborative clinical trials with these personalized anti-cancer vaccines. “The neoantigen supply chain is focused on efficiency and speed. To meet this need, we have …

Pepscan doubles GMP production capacity to facilitate clients’ growth

Juul Zwinkels News releases

Today, Pepscan announced that its GMP production capacity has doubled. Pepscan is an all-in-one partner in peptides, building on 25 years of experience in advancing and applying peptide expertise to facilitate clients in the development and production of peptides. The doubled GMP production capacity enables Pepscan to guarantee short production timelines. It also gives clients the benefit of collaborating with a single expert partner on the way from R&D to the clinic, resulting in maximum efficiency while also saving time. …

CLIPS scaffolds used in phage display to boost drug discovery

Juul Zwinkels News releases

Phage display is a technology that allows de novo discovery of peptidic binders against any protein target of interest by exploring DNA-encoded peptide libraries, exceeding billions of different members. Our team of experts developed a unique phage display platform for the discovery of high-quality lead candidates with affinity for clients’ targets. Unique CLIPS scaffold portfolio By incorporating Pepscan’s unique CLIPS scaffold portfolio, we optimized our phage display platform for the identification of CLIPS constrained peptides, a class of highly-constrained peptides …

Passion for Peptides – The people behind Pepscan

Juul Zwinkels News releases

“Solving the puzzle brings me the greatest pleasure” Jeroen Bouwhuis has been working at Pepscan for almost six years. “I started here as an intern, and over the years I’ve really grown into the company.” Besides being one of the individuals responsible for manufacturing high-quality peptides, Jeroen is part of Pepscan’s Manufacturing, Science and Technology (MS&T) team led by Chief Scientific Officer Peter Timmerman. “What I really like about Pepscan is that we try to serve our clients under almost …

Clinical peptides for innovative personalized cancer vaccine trial

Silvia Boelens Featured Product News releases

June 25, 2019, Lelystad, The Netherlands – Pepscan has positioned itself as a critical partner in a collaborative clinical trial with personalized anti-cancer vaccines. In this trial, Pepscan is solely responsible for production of clinical neoantigen peptides, tailored to tumors of individual patients. Neoantigens, or tumor-specific antigens, are peptide sequences uniquely identified in proteins expressed in tumor cells from individual patients. Pepscan’s in vitro synthesized neoantigen peptides constitute the core active ingredient of the anti-cancer vaccines. These vaccines are designed …

Access to latest paper about RGD-peptide screening in ELISA

Silvia Boelens News releases

Pepscan’s scientists have developed a highly sensitive ELISA-method to measure integrin-binding of RGD-peptides without using cells, ECM-proteins or antibodies. The main benefits of this assay are the low integrin consumption and the fact that it is suitable for high-throughput screening of (RGD-)peptide libraries. Now the article is available online (open access), please click on the link to get further information about the article.

Tetracyclic peptides via a novel ‘Triple-C locking’ technology

Evert van Dijk News releases

Congratulations to our scientists! Pepscan’s scientists have developed a brand-new technology for the synthesis of highly constrained tetracyclic peptides in a collaborative project together with the University of Amsterdam, EnzyPep B.V. and Maastricht University. The method is based on the cyclization of linear peptides via a one-pot ‘Triple-C (CEPS/CLIPS/CuAAC) locking’ procedure, thereby enabling the general and facile production of isomerically pure tetracyclic peptides. The authors have reported their findings in the peer-reviewed journal ChemBioChem. The authors believe that the novel …

Pepscan wraps up successful Dutch Peptide Symposium 2018

Evert van Dijk News releases

It was our pleasure to welcome peptide society to Maastricht for the 26th edition of the Dutch Peptide Symposium. Following the successful meeting in Eindhoven, this years’ peptide symposium organized by Pepscan with collaboration of Maastricht University at Crowne Plaza Maastricht, which brought people together from academia and industry. The symposium focused on 12 short oral abstract lectures from Dutch and international youngster peptide researchers, which were ranked and selected by our scientific committee. Moreover 25 scientists presented exciting novel …

Potential breakthrough therapy for cancer based on CLIPS technology

Evert van Dijk News releases

Lelystad, 6 July 2017 – Pepscan, the Dutch biotech company specialized in protein mimicry for the discovery of therapeutics peptides, announced today important progress with a drug development program based on its proprietary CLIPS technology. A team of Bicycle Therapeutics in the UK applied Pepscan’s CLIPS technology to identify a bicyclic CLIPS peptide that selectively binds to a protein (MT1-MMP) present on tumor cells. They subsequently linked a toxin payload to the high affinity bicyclic peptide, to create a ‘Bicycle …

We use cookies to ensure that we give you the best experience on our website. If you would like to, you can change your cookie settings in your browser.
For more information check our privacy policy
Find out more
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Cookie Settings
Accept All Cookies